Neuromyelitis optica spectrum disorder(NMOSD)is a immune-mediated demyelinating disease of the central nervous system,characterized by high recurrence and disability rates.Preventing relapses is crucial in the treatment of this condition.Monoclonal antibodies have emerged as a novel and rapidly evolving clinical therapeutic strategy targeting NMOSD in recent years.An increasing number of studies and clinical trials have also confirmed the effectiveness and safety of monoclonal antibodies.Rituximab,a monoclonal antibody targeting the B-cell surface antigen CD20,has been widely used in the treatment of NMOSD.Currently,in China,the only approved monoclonal antibody for treating NMOSD is Inebilizumab,which targets the B-cell surface antigen CD 19.Additionally,various monoclonal antibodies,such as interleukin-6 receptor inhibitors and complement C5 inhibitors,have been used in the treatment of NMOSD.With the deepening of the research on the pathogenesis of NMOSD,the molecular mechanism of disease-related immune network is further clarified,and multi-center clinical trials are widely carried out.More accurate monoclonal antibody treatment strategies for NMOSD will be applied to clinical practice,benefiting more patients.
维普
万方数据